Holzkirchen, 25 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.
“Today’s CHMP positive opinion brings us one step closer to strengthening our epoetin alfa product offering which has already generated more than 400,0001 patient years of experience worldwide” said Carol Lynch, …